Magnetar Financial’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$297K Buy
6,187
+290
+5% +$12.5K ﹤0.01% 789
2026
Q1
$217K Buy
+5,897
New +$279K ﹤0.01% 871
2024
Q4
Sell
-333,367
Closed -$39.7M 738
2024
Q3
$39.7M Buy
333,367
+230,875
+225% +$30.8M 0.86% 40
2024
Q2
$14.6M Sell
102,492
-68,529
-40% -$9.08M 0.31% 78
2024
Q1
$22M Buy
+171,021
New +$20.4M 0.49% 68
2023
Q1
Sell
-205,082
Closed -$13.9M 687
2022
Q4
$13.9M Sell
205,082
-392,998
-66% -$23M 0.24% 114
2022
Q3
$29.8M Sell
598,080
-363,272
-38% -$19.5M 0.41% 50
2022
Q2
$53.6M Buy
961,352
+239,856
+33% +$13.3M 0.55% 32
2022
Q1
$40.1M Buy
721,496
+145,392
+25% +$7.46M 0.43% 36
2021
Q4
$32.3M Buy
576,104
+350,266
+155% +$19M 0.32% 58
2021
Q3
$10.8M Buy
+225,838
New +$10.9M 0.11% 194
2020
Q2
Sell
-88,000
Closed -$2.65M 541
2020
Q1
$2.65M Buy
+88,000
New +$2.62M 0.06% 140
2019
Q2
Sell
-105,154
Closed -$2.75M 523
2019
Q1
$2.75M Sell
105,154
-291,600
-73% -$7.17M 0.07% 88
2018
Q4
$9.14M Buy
+396,754
New +$8.82M 0.22% 55

Other funds holding NVO

Magnetar Financial's NVO Position: Q2 2026 in Review

Magnetar Financial increased its Novo Nordisk (NVO) stake by 4.9% in Q2 2026, buying an estimated $12.5K and bringing the position to 6,187 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #789.

Magnetar Financial first reported a position in NVO in Q4 2018 and has held it in 14 quarters since. The position peaked at $53.6M in Q2 2022. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Magnetar Financial held 6,187 shares of Novo Nordisk worth $297K as of Q2 2026.
  • Magnetar Financial bought 290 Novo Nordisk shares in Q2 2026, an estimated $12.5K.
  • Novo Nordisk made up ﹤0.01% of Magnetar Financial's portfolio in Q2 2026, its #789 holding.
  • Magnetar Financial first reported a position in Novo Nordisk in Q4 2018 and has held it in 14 quarters since.
  • Magnetar Financial's Novo Nordisk position peaked at $53.6M in Q2 2022.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Magnetar Financial's 13F filing for Q2 2026, filed 14 Aug 2026.